Looking at top Wall Street opinions, Bristol-Myers Squibb Company (NYSE: BMY) has recently made its way into the research list of Atlantic Equities – signaling that their analyst’s rating adjustment is noteworthy. This stock was upgraded to a rating of Overweight in the eyes of Atlantic Equities, whereas its previous rating was Neutral in the eyes of Atlantic Equities, as reported on Wednesday, August 14th, 2019. Another heavy-hitting research note was published by Goldman on Tuesday May 28th, 2019, with this firm Initiated BMY to an updated rating of Buy. In the past six months and three months of trading, shares of Bristol-Myers Squibb Company (BMY) have moved by -6.12% and 1.18%, respectively.
Brokerage Updates Related to Bristol-Myers Squibb Company (BMY) Stock
This publicly-traded organization generated gains of 4.61% over the last 5 sessions. Right now, this stock is the subject of 11 analysts’ evaluations, who – on average – have given this company’s shares a Buy rating. Not a Single analyst have given underperform rating or sell rating, and 4 have given a rating of Buy or better. Based on the 11 stock market experts following this company, the average 12-month price target is $56.00. Moreover, individual price targets range between $46.00-$66.00. With its recent move to $55.50, we can see that these firms project this stock will loss by -20.34% in one year.
Updates from Bristol-Myers Squibb Company (BMY) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.10% rise since the beginning of the calendar year. A Director at Bristol-Myers Squibb Company (BMY) bought some of its shares in a transaction that was finalized on Jul 31. Similarly, Samuels Theodore R. II bought 5,000 shares of the organization’s stock at $47.29 apiece and racked up $236,440 in earnings from the purchase.
Bristol-Myers Squibb Company (NYSE:BMY) Results in the Pipeline
The next scheduled release of financial results for Bristol-Myers Squibb Company will be for the Jun-19 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $1.06. In the same vein, they expect sales for the quarter to amount to $6,112.35 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $6,273.00 million in revenue alongside EPS at $1.18. On average, the analyst projection was calling for $5,920.00 million with $1.10 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $5,973.00 million, with earnings per share ending up at $0.94.
UnitedHealth Group Incorporated (NYSE:UNH) experienced a drop of -3.08% from the closing price in the previous trading day. That drove the price to $232.94 per share, as observed on January 1st, 1970, at a time when the total trading volume reached 4,494,504 shares of stock – compared to the typical average of 3.59M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $296.26.
Pricing Indications for UnitedHealth Group Incorporated (UNH)
This organization has had a price-to-earnings ratio of 17.49 in the last year. Meanwhile, it gained 249.30 from its observable 50-day simple moving average. Right at this moment, the per-share value is -7.34% lower than the mean per-share price over the last 200 days in the market.
UnitedHealth Group Incorporated (NYSE:UNH) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 11 have a Buy rating, 13 have an outperform rating, while 1 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 1.60 , based on information from Thomson Reuters.
UNH Stock Value Potential
In trading activity as of late, this stock’s value was 251.25 up from its 200 day moving average, while also -6.65% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $257.00-$330.00. The market value for the entire organization reached 219.46B. In the last trading session, the price ended the day at $240.35. The institutional holdings related to this organization account for 0.40%, and the Beta factor is now 0.60. This company’s RSI (Relative Strength Index) managed to hit 33.08.
UnitedHealth Group Incorporated (NYSE:UNH) Analyst Points of Focus
UnitedHealth Group Incorporated (UNH) has found itself inside of Citigroup’s research list, so their analyst rating adjustment is worth taking note of. This stock was upgraded to Buy, compared to its previous rating of Neutral by Citigroup, as garnered from a news report on Friday May 10th, 2019. An additional helpful research note was sent out by UBS’s on Tuesday April 23rd, 2019. The brokerage decided to initiated UNH to Neutral.